GET DAILY SIGNALSLabcorp (LH) Delivers Solid Q3 2026 Earnings and Raises Full-Year Guidance
Key Takeaways
- Total revenue rose 6.9% year over year to $3.81 billion, surpassing the consensus estimate of roughly $3.77 billion.
- Adjusted earnings per share (EPS) climbed 14.5% to $4.78, ahead of the approximately $4.65 consensus forecast.
- Both the Diagnostics Laboratories and Biopharma Laboratory Services segments grew, and management raised its full-year 2026 guidance.
- Free cash flow improved to $412 million from $281 million in the prior-year quarter.
- A proposed Medicare fee-schedule change under PAMA (the Protecting Access to Medicare Act) could create an estimated $125 million reimbursement headwind in 2027.
Putting the Results in Context
Labcorp Holdings Inc. (LH), one of the largest clinical laboratory networks globally, operates at the crossroads of everyday diagnostics and specialized testing. Its quarterly performance often reflects broader trends in healthcare utilization and pharmaceutical research activity. Ahead of this release, the focus was on whether volume growth and margin gains could persist amid acquisition integration and potential policy shifts in reimbursement. The third quarter marked the sixth straight period of improving enterprise margins, backed by higher volumes and operational efficiencies. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry. Demand remained firm in central lab services and specialty areas, aligning with the company’s emphasis on oncology, neurology, and women’s health, even as a proposed Medicare adjustment introduced fresh uncertainty for 2027.
Quarterly Performance Breakdown
Labcorp reported third-quarter 2026 revenue of $3.81 billion, up 6.9% from $3.56 billion a year earlier and roughly 1% above consensus. Organic growth reached 5.5%, with acquisitions adding 1.5% and currency effects subtracting a modest 0.1%.
Adjusted EPS increased 14.5% to $4.78, topping the consensus figure of about $4.65. On a GAAP basis, diluted EPS came in at $3.22 versus $3.12 in the year-ago quarter.
Diagnostics Laboratories revenue rose 6.5% to $2.95 billion, supported by 3.1% organic volume growth and 1.3% favorable price and mix. Biopharma Laboratory Services revenue advanced 8.5% to $866.7 million, including 11.5% growth in central labs. Enterprise adjusted operating margin widened 60 basis points to 15%. Management lifted its full-year 2026 outlook, now expecting revenue growth of 5.9%–6.7% and adjusted EPS of $18.30–$18.70. When reviewing the segment trends, I cross-checked comparable names through Tickeron’s AI Daily Buy/Sell Signals to gauge relative momentum.
Market Response to the Report
Shares of LH climbed about 1.4% to 1.5% in pre-market trading after the release, reflecting approval of the earnings beat and upgraded annual targets. Investors balanced the dual-segment strength and better free cash flow against the emerging reimbursement risk from the proposed PAMA changes. Management voiced concern over the preliminary schedule, which draws from limited laboratory data, and noted potential effects on patient access and sector stability. The maintained longer-term view, paired with ongoing margin improvement, helped ease some near-term worries.
Factors to Watch Ahead
Three areas stand out for LH after this update. First is the evolution of the PAMA fee schedule and its projected $125 million impact in 2027. The company continues to back the RESULTS Act and engage policymakers, though the final outcome remains fluid.
Second, progress on recent acquisitions will be closely tracked. Deals involving select BioReference Health assets, Myriad Genetics’ prenatal testing business, and Millennium Health are expected to bolster specialty and drug-testing capabilities, with their contributions to growth and margins depending on regulatory timelines.
Third, trends in specialty testing demand, central lab bookings, and the LaunchPad productivity program will indicate whether margin expansion and double-digit EPS growth can continue. Management kept its 2026–2029 long-term framework intact, but results will hinge on balancing expansion, cost control, and policy developments.
Incorporating Tickeron Tools Into My Process
When analyzing healthcare names like this one, I frequently rely on Tickeron’s AI Screener to filter for relevant peers and technical setups. It lets me quickly surface comparable stocks based on fundamentals and patterns, which helps put individual results into broader context without spending hours on manual screens.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
LH in upward trend: 10-day moving average moved above 50-day moving average on October 23, 2026
The 10-day moving average for LH crossed bullishly above the 50-day moving average on October 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 13 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 81%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 06, 2026. You may want to consider a long position or call options on LH as a result. In 58 of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 59%.
The Moving Average Convergence Divergence (MACD) for LH just turned positive on October 08, 2026. Looking at past instances where LH's MACD turned positive, the stock continued to rise in 28 of 51 cases over the following month. The odds of a continued upward trend are 55%.
LH moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +0.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where LH advanced for three days, in 192 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LH declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 53%.
LH broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for LH entered a downward trend on October 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 11 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.121) is normal, around the industry mean (65.632). P/E Ratio (27.212) is within average values for comparable stocks, (1.899). Projected Growth (PEG Ratio) (1.206) is also within normal values, averaging (3.473). LH has a moderately high Dividend Yield (0.009) as compared to the industry average of (0.002). P/S Ratio (1.876) is also within normal values, averaging (9.775).
The Tickeron Price Growth Rating for this company is 22 (best 1 - 100 worst), indicating outstanding price growth. LH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 41 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 87, placing this stock slightly better than average.
The Tickeron PE Growth Rating for this company is 54 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 65 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of medical testing services
Industry MedicalSpecialties
Advertisement